MOTS-c is a peptide encoded within the mitochondrial genome, first identified in 2015. It activates AMPK, the same cellular energy sensor triggered by physical exercise, which is why researchers describe it as an "exercise mimetic," a molecule that can reproduce several of exercise's metabolic effects. MOTS-c levels naturally decline with age, a pattern that tracks with metabolic slowdown. At Live Vital it is a physician-prescribed peptide therapy.

MOTS-c activates the AMPK pathway, which supports glucose uptake, fat oxidation, and the formation of new mitochondria. Research has linked it to improved insulin sensitivity, better glucose metabolism, and sustained energy and exercise tolerance without stimulants. It is intended to support and amplify physical activity, not to replace it.

Adults with reduced insulin sensitivity or metabolic dysfunction, people who are physically limited and want to jumpstart cellular metabolism, those looking to complement an existing exercise routine, and adults noticing age-related declines in energy or metabolic performance.

Many patients report improved energy and exercise tolerance within two to four weeks. Metabolic and insulin-sensitivity changes are typically noticed later, often by four to eight weeks. Timelines vary with baseline metabolic health and how closely you follow the broader plan.

Commonly reported side effects are injection site irritation, mild headache (rare), and temporary fatigue during initial dosing. MOTS-c is not appropriate during pregnancy or breastfeeding, with active cancer, or with mitochondrial disease, and it is used with caution in type 1 diabetes or alongside blood-sugar-lowering medications without supervision. MOTS-c is not FDA-approved and is prescribed off-label under physician supervision after intake and informed consent. Dr. Taylor reviews your history to confirm it is appropriate for you.